Skip to content

Study · Case report or series · n = 2 · 2024

1 result

Case report of the successful use of semaglutide to achieve target BMI prior to renal transplant in two patients with end-stage-kidney-disease.

Wallace R, Hamblin PS, Tully E, Tran J, Nelson C, Levidiotis V

Nephrology (Carlton, Vic.)18 Feb 2024Cited by 10 (Europe PMC)

PMID38369756 (opens in a new tab)DOI10.1111/nep.14277 (opens in a new tab)PepBankPUB-38369756
Publisher pagePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanCase report or seriesEfficacy outcome

    In two obese, non-diabetic haemodialysis patients, semaglutide was followed by weight loss of 16% and 12.6% in under 9 months.

    In plain wordsIn two obese dialysis patients without diabetes, semaglutide was followed by weight loss of 16% and 12.6%.

    Peptide
    Semaglutide
    Outcome
    DecreaseWeight loss before renal transplant listing
    Study

    n = 2

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · under 9 monthsAs given in this study (human).

    Measurements

    Weight loss
    16%
    patient 1
    Weight loss
    12.6%
    patient 2

    Source sentences

    Summary
    These patients achieved a 16% and 12.6% weight loss in under 9 months with one now waitlisted and the other transplanted.
    1 context sentence
    Summary · context
    This paper outlines the successful use of semaglutide to achieve a target body mass index (BMI) prior to renal transplant wait-listing in two obese, non-diabetic, HD patients.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.